Considering that NF-kB is a molecule of great importance in the initiation, promotion and progression of tumours and that NAC acts on the inactivation of this pathway with a tumoural-specific toxicity, we suggest that NAC is a promising agent for use in HCC, primarily or as an adjuvant with IFN-α. The gene discussed is IFNA2; the disease is neoplasm.